259 results on '"Murakami, S"'
Search Results
2. EP11.01-11 Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
3. P1.22-14 A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC
4. Data assimilation and control system for adaptive model predictive control
5. 1580 The role of dendritic cell-regulatory T cell crosstalk in human head and neck cancer
6. A comprehensive study of complex non-adiabatic exciton dynamics in MoSi2N4
7. 1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial disease on OsimertiNib resistAnce (TORG 1938)
8. EP11.01-008 Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System
9. EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
10. ASTI: Data assimilation system for particle and heat transport in toroidal plasmas
11. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
12. Prioritising low-risk and high-potential circular economy strategies for decarbonisation: A meta-analysis on consumer-oriented product-service systems
13. Bonding Durability of Resin Cement to Lithium Disilicate Glass Ceramics
14. Overview of recent progress on steady state operation of all-metal plasma facing wall device QUEST
15. The Comparison of Postoperative Pain Between Umbilical and Suprapubic Incision in Laparoscopic Liver Resection
16. Dayside cloud top structure of Venus retrieved from Akatsuki IR2 observations
17. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
18. Three-year overall survival update from the PACIFIC trial
19. Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
20. EP1.16-38 Pulmonary Infiltrates in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
21. Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
22. P1.01-102 Actionable Gene Aberration and the Response of Matched Therapy Among Patients with Non-Small-Cell Lung Carcinoma
23. EP1.01-72 Treatment Outcome of 2nd Generation EGFR-TKI for Non-Small Cell Lung Cancer
24. P1.01-103 Preliminary Results of Brigatinib in Japanese Patients (Pts) Who Previously Received Alectinib: Brigatinib-2001 Study
25. EP1.01-51 Efficacy Impact of Serum VEGF for Elderly or Poor PS Patients Receiving Anti-PD-1 Antibody with Advanced Non-Small Cell Lung Cancer
26. 28-GHz ECHCD system with beam focusing launcher on the QUEST spherical tokamak
27. Estimation of fuel particle balance in steady state operation with hydrogen barrier model
28. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)
29. Consideration of optimal postoperative adjuvant therapy for HER2-positive, Stage I pT1N0 cases
30. P050 Long-Term Survival of Stage IIIA-N2 NSCLC Patients with Interstitial Lung Diseases
31. OA04 Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs
32. PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
33. P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy after Nivolumab in Patients With Advanced NSCLC
34. P080 Efficacy and Safety of Docetaxel Plus Ramucirumab: A Consecutive Analysis of 68 Patients with Advanced NSCLC
35. Clinical courses of patients with small cell lung cancer after complete resection followed by adjuvant chemotherapy
36. Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
37. Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody
38. Overview of the ITER remote maintenance design and of the development activities in Europe
39. Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients
40. MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
41. P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%
42. P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study
43. PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
44. Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): Consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)
45. P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC
46. Relationship between developmental toxicity of multi-wall carbon nanotubes and lung inflammation in pregnant mice after repeated intratracheal instillation
47. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
48. Validity of wearable breath monitoring system using stretchable strain sensors in walking
49. 233O Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes
50. PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.